Analytical platform for tumor microenvironment analysis

BostonGene predicts prognosis in the majority of solid tumors and can guide immunotherapy treatment strategy in certain cancer types by classifying patient tumors into 4 distinct tumor microenvironment (TME) types from RNA-seq data.

Immune-enriched TME

SUPERIOR PROGNOSIS

High levels of immune infiltrate

Immune-enriched, Fibrotic TME

High angiogenesis and CAFs activation

Desert TME

Minimal immune infiltration, highest malignant cell percentage

Fibrotic TME

WORST PROGNOSIS

Minimal immune infiltration, high angiogenesis and CAFs activation

Cancer type-specific TME classification

Each cancer type has a unique gene expression profile that influences tumor behavior. BostonGene's advanced analysis accounts for these cancer type-specific differences to ensure precise TME classification.

Pan-solid

Melanoma

Lung Adenocarcinoma

Gastric Adenocarcinoma

Urothelial Cancer

Sarcoma

Diffuse Large B-cell Lymphoma

Follicular Lymphoma

Mantle Cell Lymphoma

”A tumor ‘‘personality’’ test: the BostonGene MF Portrait™ serves as a roadmap to guide treatment decision-making, drawing from both the genomic and the local microenvironmental landscape of the tumor.”

Christina Curtis

PhD, MSc, Associate Professor of Medicine and Genetics, Co-Director, Molecular Tumor Board, Stanford Cancer Institute

BostonGene advances TME research

Visit Publications

Cancer Cell • May 1, 2021

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

Article

Blood Cancer Journal • October 12, 2023

Immune-depleted tumor microenvironment is associated with poor outcomes and btk inhibitor resistance in mantle cell lymphoma

Article

Gastroenterology • May 6, 2024

Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer

Article

Cancer Discovery • June 1, 2021

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

Article

Visit Publications